143 related articles for article (PubMed ID: 34464888)
1. Concomitant occurence of multiple autoantibodies against human cytochromes P450.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Int Immunopharmacol; 2021 Nov; 100():108087. PubMed ID: 34464888
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of autoantibodies against CYP4Z1 in patients with colon, ovarian, or prostate cancer.
Khayeka-Wandabwa C; Ma X; Jia Y; Bureik M
Immunobiology; 2022 Mar; 227(2):152174. PubMed ID: 34999392
[TBL] [Abstract][Full Text] [Related]
3. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
[TBL] [Abstract][Full Text] [Related]
4. High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.
Luo R; Zheng C; Song W; Tan Q; Shi Y; Han X
Cancer Sci; 2022 Feb; 113(2):770-783. PubMed ID: 34843149
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
Miyakawa H; Kitazawa E; Kikuchi K; Fujikawa H; Kawaguchi N; Abe K; Matsushita M; Matsushima H; Igarashi T; Hankins RW; Kako M
Autoimmunity; 2000; 33(1):23-32. PubMed ID: 11204250
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic efficiency of seven autoantibodies in lung cancer.
Huang H; Luo W; Ni Y; Sun S; Wang C; Zhang L
Eur J Cancer Prev; 2020 Jul; 29(4):315-320. PubMed ID: 31764214
[TBL] [Abstract][Full Text] [Related]
7. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
[TBL] [Abstract][Full Text] [Related]
8. Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis.
Wang Y; Wang P; Liu M; Zhang X; Si Q; Yang T; Ye H; Song C; Shi J; Wang K; Wang X; Zhang J; Dai L
J Immunol Methods; 2021 May; 492():112991. PubMed ID: 33587914
[TBL] [Abstract][Full Text] [Related]
9. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 expression (CYP) in non-small cell lung cancer.
Oyama T; Sugio K; Uramoto H; Kawamoto T; Kagawa N; Nadaf S; Carbone D; Yasumoto K
Front Biosci; 2007 Jan; 12():2299-308. PubMed ID: 17127240
[TBL] [Abstract][Full Text] [Related]
11. Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases.
Obermayer-Straub P; Strassburg CP; Manns MP
Can J Gastroenterol; 2000 May; 14(5):429-39. PubMed ID: 10851284
[TBL] [Abstract][Full Text] [Related]
12. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.
Manns MP; Obermayer-Straub P
Hepatology; 1997 Oct; 26(4):1054-66. PubMed ID: 9328334
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma.
Li Y; Li CQ; Guo SJ; Guo W; Jiang HW; Li HC; Tao SC
EBioMedicine; 2020 Mar; 53():102674. PubMed ID: 32113159
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
[No Abstract] [Full Text] [Related]
15. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
17. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
18. Serum APE1 autoantibodies: a novel potential tumor marker and predictor of chemotherapeutic efficacy in non-small cell lung cancer.
Dai N; Cao XJ; Li MX; Qing Y; Liao L; Lu XF; Zhang SH; Li Z; Yang YX; Wang D
PLoS One; 2013; 8(3):e58001. PubMed ID: 23472128
[TBL] [Abstract][Full Text] [Related]
19. Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules.
Huo Y; Guo Z; Gao X; Liu Z; Zhang R; Qin X
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3349-3357. PubMed ID: 32648227
[TBL] [Abstract][Full Text] [Related]
20. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
